Prevalence of cardiac conduction disturbances during carbamazepine treatment: preliminary data.
Twenty-five epileptic patients chronically treated with carbamazepine underwent 24 h electrocardiogram (ECG) monitoring in order to evaluate the prevalence of cardiac conduction abnormalities. Plasma levels of carbamazepine and its metabolite, carbamazepine-10,11-epoxide, were determined by liquid chromatography. Six patients had mild ECG abnormalities. These patients did not differ from the others with respect to plasma concentrations of the drug and its metabolite.